mRNA Vaccines

Foreword - RNA technology overview

Dong Yu (dong.x.yu@gsk.com) (GSK) & Frank Bähner (Frank.Baehner@curevac.com) (CureVac) - confirmed

Conventional mRNA-based technology & mode of action

Benjamin Petsch (benjamin.petsch@curevac.com) (CureVac) - confirmed

Self-amplifying RNA-based technology & mode of action

Jeffrey Ulmer (jeffrey.b.ulmer@gsk.com)/Dong Yu (dong.x.yu@gsk.com) (GSK) - confirmed

Delivery and formulation technologies

Yizhou Dong (dong.525@osu.edu) (Ohio State) - confirmed

RNA for infectious disease applications

Drew Weissman (dreww@pennmedicine.upenn.edu) (U Penn) - confirmed

RNA for other indications (immunotherapies/oncology, molecular therapies - a potential topic)

Tim Wagenaar (Timothy.Wagenaar@sanofi.com) (Sanofi) - tentatively confirmed, likely working with Biotech; Backup - Katalin Karikó (BioNTech)

Production and capabilities

Heinrich Haas (Heinrich.Haas@biontech.de) (Biontech) - waiting for response; Backup - Juan Andres (Moderna)

Clinical development

Tal Zaks (Tal.Zaks@modernatx.com) (Moderna) - tentatively confirmed; Backup - Anna Collén (AstraZeneca)

Other considerations (e.g., safety, regulatory issues, challenges)

Mark Tracy (mark@tracybioconsulting.com) (Tracy Bioconsulting) - waiting for response